Abstract
β-Thalassemia is a significant public health problem in Egypt. Infectious complications represent the second most common cause of mortality and the major cause of morbidity in β-thalassemia major (BTM). The increased susceptibility of these patients to infectious diseases has been attributed to the abnormalities of the immune system, which is evident by systemic inflammation and immune deficiency. In a case control study, 35 patients with BTM were compared with 30 sex- and age-matched children who served as controls. Serum ferritin, high-sensitive CRP (hsCRP), leptin and adiponectin levels were determined in all subjects. Apoptosis of neutrophils and lymphocytes was measured by the Annexin V-fluoroisothiocyanate binding assay. Serum leptin was significantly lower in patients when compared to controls. In contrast, adiponectin and hsCRP levels were significantly higher in the patients than the controls. Positive correlation was found between adiponectin and hsCRP. BTM patients had significantly higher total leukocytes, neutrophils and lymphocytes compared with controls. BTM children exhibited a significantly increased apoptosis in T-lymphocytes; however, there was no significant difference in the percentage of apoptosis of B-lymphocytes and neutrophils between the patients and the controls. There was a significant negative correlation between serum leptin and the percentage of apoptotic T-lymphocytes. Our BTM patients had a high percentage of apoptotic T-lymphocyte in comparison with controls. In addition, they had disturbed serum levels of adipocytokines and inflammatory markers. These derangements could have a role in the immunological disturbance observed in thalassemic patients.
Similar content being viewed by others
References
Fahim FM, Saad K, Askar EA, et al. Growth parameters and vitamin D status in children with thalassemia major in upper Egypt. Int J Hematol Oncol Stem Cell Res. 2013;7(4):10–4.
Shawky RM, Kamal TM. Thalassemia intermedia: an overview. Egypt J Med Hum Genet. 2012;13:245–55.
Farmakis D, Giakoumis A, Polymeropoulos E, et al. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit. 2003;9(1):RA19–22.
Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–93.
Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis. 2009;1(1):e2009028.
Enli Y, Balci YI, Gönen C, et al. Adipocytokine concentrations in children with different types of beta-thalassemia. Scand J Clin Lab Invest. 2014;74(4):306–11.
Chaliasos N, Challa A, Hatzimichael E, et al. Serum adipocytokine and vascular inflammation marker levels in beta-thalassaemia major patients. Acta Haematol. 2010;124:191–6.
Kanavaki I, Makrythanasis P, Lazaropoulou C, et al. Soluble endothelial adhesion molecules and inflammation markers in patients with beta-thalassemia intermedia. Blood Cells Mol Dis. 2009;43(3):230–4.
Paz-Filho GJ, Delibasi T, Erol HK, et al. Cellular immunity before and after leptin replacement therapy. J Pediatr Endocrinol Metab. 2009;22(11):1069–74.
Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med. 2012;33:35–45.
Sun Y, Xun K, Wang C, et al. Adiponectin, an unlocking adipocytokine. Cardiovasc Ther. 2009;27:59–75.
Makis A, Challa A, Hatzimichael E, et al. Adipocytokines are related to haemolytic and inflammatory biomarkers in sickle cell beta thalassaemia. Br J Haematol. 2013;163(1):142–4.
Shahramian I, Akhlaghi E, Ramezani A, et al. A study of leptin serum concentrations in patients with major beta-thalassemia. Iran J Ped Hematol Oncol. 2013;3(2):59–63.
Moshtaghi-Kashanian GR, Razavi F. Ghrelin and leptin levels in relation to puberty and reproductive function in patients with beta-thalassemia. Hormones. 2009;8(3):207–13.
Choobineh H, Dehghani SJ, Alizadeh SH, et al. Evaluation of leptin levels in major beta thalassemic patients. Int J Hematol Oncol Stem Cell Res. 2010;3(4):1–4.
Karachaliou F, Vlachopapadopoulou E, Theochari M, et al. Leptin levels in patients with thalassemia major. Minerva Pediatr. 2006;58(4):373–8.
Al-Awadhi AM, Alfadhli SM, Al-Khaldi D, et al. Investigation of the distribution of lymphocyte subsets and zinc levels in multitransfused beta-thalassemia major patients. Int J Lab Hematol. 2010;32(2):191–6.
Grady RW, Akbar AN, Giardina PJ, et al. Disproportionate lymphoid cell subsets in thalassemia major: the relative contributions of transfusion and splenectomy. Br J Haematol. 1985;59:713–21.
Dwyer J, Wood C, McNamara J, et al. Abnormalities in the immune system of children with beta-thalassemia major. Clin Exp Immunol. 1987;68:621–9.
Pattanapanyasat K, Thepthai C, Lamchiagdhase P, et al. Lymphocyte subsets and specific T-cell immune response in thalassemia. Cytometry. 2000;42(1):11–7.
Oren H, Sahin B, Irken G, et al. Neutrophil apoptosis in patients with beta-thalassemia major. Pediatr Hematol Oncol. 2003;20(3):237–43.
Khalifa AS, Fattah SA, Maged Z, et al. Immunoglobulin levels, opsonic activity and phagocytic power in Egyptian thalassemic children. Acta Haematol. 1983;69(2):136–9.
Fujita Y, Murakami M, Ogawa Y, et al. Leptin inhibits stress-induced apoptosis of T lymphocytes. Clin Exp Immunol. 2002;128(1):21–6.
Fernández-Riejos P, Najib S, Santos-Alvarez J, et al. Role of leptin in the activation of immune cells. Mediators Inflamm. 2010;2010:568343.
Walter PB, Porter J, Evans P, et al. Increased leucocyte apoptosis in transfused β-thalassaemia patients. Br J Haematol. 2013;160:399–403.
Scheel-Toellner D, Wang K, Craddock R, et al. Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood. 2004;104(8):2557–64.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Elsayh, K.I., Mohammed, W.S., Zahran, A.M. et al. Leukocytes apoptosis and adipocytokines in children with beta thalassemia major. Clin Exp Med 16, 345–350 (2016). https://doi.org/10.1007/s10238-015-0361-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-015-0361-6